Because of the limitations of current scaffolds and unfavorable results of clinical trials, proper scaffolds facilitating bladder reconstruction are highly desirable. The aim of this study was to evaluate a novel asymmetric bilayer chitosan scaffold compared with conventional bladder acellular matrix graft (BAMG) in a rat model of bladder augmentation. Twenty-four 8 week-old male Sprague-Dawley rats were randomly assigned to the chitosan scaffold, BAMG and cystotomy groups. The rats' bladders were sampled for cystography and routine histological examination at 21 and 70 days. Immunofluorescence photometry, conscious cystometry, quantitative real-time polymerase chain reaction, and western blot analyses were performed using bladders at 70 days. Compared with BAMG, the chitosan scaffold consisted of a membrane-like compact layer and a sponge-like porous layer with an excellent combination of mechanical strength and flexibility. The chitosan group showed better performances than the BAMG group in radiographic cystography, smooth muscle regeneration, blood vessel numbers and functional restoration. In contrast to reduced bladder compliance induced by BAMG, bladder augmented by chitosan displayed nearly 1.5-fold increased bladder capacity with comparable compliance to that of the cystotomy group at 70 days. The chitosan group exhibited higher levels of VEGF and VEGFR2, associated with the activation of the hypoxia-related SDF-1a/CXCR4 pathway. These results suggested that the asymmetric bilayer chitosan scaffold is a promising scaffold for bladder reconstruction.
Introduction
Bladder augmentation is a surgery indicated in patients without adequate bladder capacity or detrusor compliance due to neuropathic causes (e.g., spinal cord injury, multiple sclerosis, myelodysplasia) or non-neuropathic causes (chronic, interstitial, or radiation cystitis, detrusor instability, exstrophy, defunctionalized bladder). [1] [2] [3] In 35 children's hospitals in the United States, 665 children with spina bida underwent bladder augmentation over a 5 year period. 4 Enterocystoplasty is the primary option for bladder augmentation, which is associated with a number of problems and complications, including malignancy, bowel obstruction, bladder perforation, urinary tract infection, and gastrointestinal dysfunction. 5 In addition, when the intestine is used as tissue donor, some complications may arise such as improper bowel anastomosis, perforation, and calculi. 6 Tissue donor complications could be avoided using tissue engineering. 7 Various scaffolds have been tested to facilitate bladder tissue engineering, either supplemented with cells and/or growth factors. 8 Unfortunately, postoperative bladder capacity was not augmented compared to preoperative status in large animals according to a systematic review. 9 Although collagen-based scaffolds showed promising short-term outcomes in a pilot clinical trial, 10 the favorable outcomes in preclinical studies were not substantiated in recent clinical trials that tested the long-term follow-up of polyglycolic-acid (PGA)/poly (lactic-co-glycolic acid) (PLGA) copolymer and small intestinal submucosa (SIS). 11, 12 Synthetic polymers such as PGA and PLGA were denoted by its inclination to inammation and brosis, as well as unsatised degradation rate. 13 Naturally derived acellular biomatrices served as conventional scaffolds for tissueengineered bladder augmentation, represented by SIS, amniotic membrane and bladder acellular matrix gra (BAMG). BAMG has been extensively used with good biocompatibility and proved efficacy to support urothelial regeneration.
14 Its failure in large bladder defect repair was largely owed to its insufficiency in facilitating smooth muscle regeneration, angiogenesis and innervation in our previous study. 15 Moreover, scaffold shrinkage and perforation were frequently reported by simple application of BAMG or SIS.
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The current goals of scaffolds in bladder reconstruction are not only to support de novo tissue regeneration, but also to facilitate functional restoration. Showing high safety, good biocompatibility, diverse plasticity, and tunable biodegradability, chitosan is a proper candidate scaffold for bladder reconstruction. 18 Approved by the US Food and Drug Administration for human use, chitosan is a natural copolymer derived from the alkaline deacetylation of chitin, which is derived from exoskeletons of crustaceans and from cell walls of fungi or insects. 19 Its bacteriostatic and fungistatic properties are crucial for bladder reconstruction because the urinary tract is oen colonized with various bacterial strains. 20 Furthermore, the cationic nature of chitosan allows it to retain and concentrate a large number of cytokines and growth factors which are linked to anionic glycosaminoglycans, proteoglycans, and other negatively charged molecules. 21 We hypothesized that our newly fabricated asymmetric bilayer chitosan scaffold could solve the aforementioned disadvantages of BAMG by increased porosity and strengthened mechanical properties. This study aimed to evaluate the novel asymmetric bilayer chitosan scaffold in a rat model of bladder augmentation compared with BAMG.
Experimental

Animals
Twenty-four 8 week-old male Sprague-Dawley rats matched for body weight were housed in wire-oored cages with free access to food and water in a temperature-controlled pathogen-free animal facility (20) (21) (22) C, humidity 40-70%, 12/12 h day per night cycle). The rats were acclimatized for a week before experiments. The rats were then randomized to the bilayer chitosan scaffold group (chitosan group), the BAMG group, and the cystotomy control groups (cystotomy group) (n ¼ 8/group). The rats in each group were further randomized to two evaluation time-points (21 and 70 days aer operation) (n ¼ 4/ subgroup). Body weight was recorded before and aer surgery. Post-operational bladder calculus was measured as number and total weight. All animal procedures were approved and supervised by the Animal Experimental Ethical Inspection of Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, under number HKDL [2016] 149 and were performed in accordance with the guidelines of the China Act on Welfare and Management of Animals.
Biomaterials
The asymmetric bilayer chitosan scaffold was made using a novel self-deposition technique developed by our team.
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Briey, chitosan (Haihui Bioengineering Co. Ltd., Qingdao, China) was dissolved in 1% (v/v) acetic acid to generate a 2.5% (w/v) solution. The solution was precipitated with 1 M NaOH added dropwise to form micro-hydrogels. Then, these microhydrogels were washed to neutral pH with tri-distilled water and poured in the mould for self-deposition and to drain off the remaining water. The compact membrane-like layer was obtained by drying the micro-hydrogels at 60 C under vacuum, while the porous sponge-like layer was achieved by freezedrying. Using sprayed medical a-cyanoacrylate, the two layers were combined (mass ratio of 3 : 2) at room temperature for 1 min to obtain the asymmetric bilayer chitosan scaffold. BAMG was made according to the decellularization protocol used in our previous work, in which complete elimination of cellular nuclei was conrmed by histology and residual DNA. 
Scanning electron microscopy (SEM)
A SEM was used to observe scaffolds' surface morphology, inner space, and thickness as previously described. 24 Chitosan and BAMG scaffolds were cut into 7 Â 7 mm pieces and prexed with 2% glutaraldehyde at 4 C for 2 h, washed twice with PBS, and post-xed in 1% osmic acid at 4 C for 2 h. Aer two washes with distilled water, the samples were dehydrated with gradient ethanol and dried to a critical point. The samples were then mounted, sputter-coated with gold in a caster (NeoCaster, MP-1920NCTR, JEOL, Tokyo, Japan), and examined under a SEM (NeoScope, JCM-5100, JEOL, Tokyo, Japan) at cross-section, topview, and bottom-view at 20-25 kV with different magnications.
Micro-computed tomography (mCT)
The microstructure analysis of the bilayer chitosan was performed by the mCT system (SkyScan-1176, Bruker microCT, Kontich, Belgium). Because the BAMG is a single-layer membrane with dense structure, it was not investigated by the mCT system. Scans of the whole bilayer chitosan scaffold (2.6 Â 3.0 cm) were performed using 8.96 mm voxel size, 40 kV, 2000 mA and 0.45 degrees rotation step. The compact layer of the chitosan scaffold was not evaluated because of its dense structure. For the porous layer of the chitosan scaffold, mCT evaluation was performed on four randomly selected cylinders regions with a diameter of 0.3 mm and height of 7.0 mm. Aer three-dimensional reconstruction, the CT Analyzer 1.16.4.1 (Bruker microCT, Kontich, Belgium) was used for microstructure analysis. The indexes including pore size, porosity and pore interconnectivity were calculated for the porous layer of the chitosan scaffold.
Mechanical properties
Each scaffold was cut into a dog-bone shape (10 Â 40 mm) and hydrated in PBS for 1 day to reach a swelling equilibrium. Samples were subjected to mechanical testing using a biomechanical analyzer (Instron 5542, Illinois Tool Works Inc., IL, USA) to measure maximal load and elastic modulus as previously described. 25 The interval length of the two grippers was set at 10 mm with a gradual moving speed of 25 mm min À1 until the complete rupture of the scaffolds.
Bladder augmentation, catheterization, and conscious cystometry
Aer anesthesia by intraperitoneal injection of pentobarbital (30 mg kg À1 ), the bladder was exposed (Fig. 1A ) and xed by atraumatic forceps (Fig. 1B) . The anterior portion of the bladder that was immediately distal to the dome was incised longitudinally in the midline (approximately 1 cm) (Fig. 1C) . The bladder defect was marked by four non-absorbable 5-0 polypropylene sutures in each corner, and anastomosed with scaffolds by absorbable 8-0 polyglactin sutures (Ethicon, Johnson & Johnson Services, Inc., NJ, USA) in a running continuous fashion (Fig. 1D ). The cystotomy group underwent bladder incision and immediate closure with the same incision size.
Prior to conscious cystometry at 70 days aer operation, the bladder was catheterized with a PE-50 tube as previously described. 26 A slack purse-string suture was made on the dome of the bladder, in the center of which a hole opening was pierced by an 18 G needle (Fig. 1E) . The PE-50 tube was inserted through the opening and the purse-string suture was pulled tight (Fig. 1F ). Room temperature normal saline was infused into the bladder to test the suture (Fig. 1G) . The dorsal PE-50 tube was coiled in a subcutaneous pouch in the neck (Fig. 1H) , which was closed with interrupted 5-0 polypropylene sutures. To prevent infections, 30 mg kg À1 cefazolin sodium was administered subcutaneously. On the day of conscious cystometry, the coiled PE-50 tube was released from the subcutaneous pouch and connected to a pressure transducer (Laborie Medical Technologies, Brossard, Canada) and an infusion pump (infusion speed: 35 ml h À1 ) via a 3-way stopcock. The rat was placed in a metabolic cage without restraint. Its voiding volume was recorded by a gravity transducer. Aer the intra-vesical pressure curve became stable, at least three micturition cycles were recorded for urodynamic parameters analysis. Cystometrogram was drawn using the Origin 9.0 (Origin Lab, Northampton, MA, USA).
Retrograde cystography and gross bladder morphology
At 21 and 70 days post implantation, the rats' bladders were injected with contrast medium (30% iopamidol, GE Healthcare, IL, USA) through intra-vesical instillation until rst urethral urine leakage under general anesthesia (pentobarbital, 30 mg kg À1 , intraperitoneal). X-ray lm was obtained for each experimental subject. Aerwards, the bladder was extruded and the gross morphology was examined in vivo.
Bladder calculus analysis
The bladder calculus compositions were analyzed by an infrared spectrum automatic analysis instrument (LIIR-20, Lanmode Scientic Instrument Co. Ltd., Tianjin, China) according to manufactural protocol. Bladder calculus was rinsed with distilled water and then dried at room temperature. The samples were rubbed into powder, mixed with potassium bromide (KBr) at a ratio of 1 : 50, and pressed into thin slices (thickness of 1 mm) under spectrum analysis.
Histology
The rats were euthanized by CO 2 asphyxiation and the bladders were excised for standard histological processing at 21 and 70 days post implantation. 27 Aer embedding in paraffin in an axial orientation to capture the entire circumferential surface, bladder sections (10 mm) were cut and stained with hematoxylin and eosin (H&E) and Masson's trichrome stains (MTS). Immunouorescence analysis was carried out to detect cytokeratin (CK, AE1/AE3) for urothelium, a-smooth muscle actin (a-SMA) for smooth contractile muscle, CD31 for vessels, and NeuN for neuron buttons at 70 days post-operation. The following primary antibodies were used: anti-cytokeratin AE1/AE3 (1 : 50 dilution, ab1747070, Abcam, Cambridge, MA, USA), anti-a-SMA (1 : 150 dilution, ab32575, Abcam, Cambridge, MA, USA), anti-CD31 (1 : 100 dilution, ab119339, Abcam, Cambridge, MA, USA), and anti-NeuN (1 : 150 dilution, ab177487, Abcam, Cambridge, MA, USA). Sections were incubated with speciesmatched uorescein isothiocyanate (FITC)-conjugated secondary antibodies (Millipore, Billerica, MA, USA) and nuclei were counterstained with 4 0 ,6-diamidino-2-phenyllindole (DAPI). Specimens were visualized using a Nikon Eclipse 80i uorescence microscope (Nikon Instruments Inc., Tokyo, Japan) and representative images were acquired using NISElements 4.0 (Nikon Instruments Inc., Tokyo, Japan). The percentages of the corresponding protein positive expression per total area were calculated by ImageJ 1.50i (National Institutes of Health, Bethesda, MD, USA) from six randomly selected elds of three slides.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted from the regenerated bladder tissue using Trizol (Invitrogen Inc., Carlsbad, CA, USA). cDNA was synthesized by reverse transcription of total RNA using the Hiscript Reverse Transcriptase (Vazyme Biotech Co. Ltd., Nanjing, China), according to the manufacturer's instructions. cDNA products were diluted 10 times, 4 ml was used as the templates for qRT-PCR. The expression of vascular endothelial growth factor (VEGF), VEGF receptor 2 (VEGFR2), stromal cellderived factor-1a (SDF-1a), and CXC chemokine receptor 4 (CXCR4) was determined in an Eco™ Real-Time PCR System (ABI7900, Illumina, Inc., San Diego, CA, USA) with the Power SYBR Green PCR master mix (2Â) (Vazyme Biotech Co. Ltd., Nanjing, China). qRT-PCR was performed with a protocol of: (1 . The primers for qRT-PCR are listed in Table 1 . Three bladders from each group at 12 weeks post-operation were used for qRT-PCR. Each assay was performed in triplicate.
Western blot analysis
The protein in the bladder samples were harvested by radioimmunoprecipitation assay (RIPA) lysis buffer, quantied by a bicinchoninic acid (BCA) Protein Assay Kit (Beyotime Biotechnology, Shanghai, China), and separated by 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis. Then, the samples were subjected to immunoblotting with antibodies to VEGF (1 : 1000, ab32152, Abcam, Cambridge, MA, USA), VEGFR2 (1 : 300, Sc-6251, Santa Cruz Biotechnology, Inc., Dallas, TX, USA), SDF-1a (1 : 500, ENT4225, Elabscience Biotechnology Co. Ltd., Wuhan, China), and CXCR4 (1 : 100, ab124824, Abcam, Cambridge, MA, USA), and were then transferred onto polyvinylidene uoride membranes (Millipore, Darmstadt, Germany). The membranes were blocked in 5% non-fat milk for 2 h at room temperature and incubated with primary antibodies overnight at 4 C, followed by incubation with horseradish peroxidase-conjugated secondary antibodies (BA1054, 1 : 50 000, Boster Biological Technology Co. Ltd., Wuhan, China) for 2 h at room temperature. The protein bands were visualized with an enhanced chemiluminescence detection kit (NCI5079, Thermo Fisher Scientic Inc., MA, USA) on X-ray lms (XBT-1, Eastman Kodak Company, NY, USA). b-Actin (1 : 200, BM0627, Boster Biological Technology Co. Ltd., Wuhan, China) was used as an internal control.
Statistical analysis
All data were expressed as mean AE standard deviation. Statistical analyses were performed using two-tailed Student's t-test or one-way analysis of variance (ANOVA) with the Bonferroni post hoc test in GraphPad Prism 5.01 (GraphPad Soware Inc., San Diego, CA, USA). Two-sided P-values < 0.05 were considered statistically signicant.
Results and discussion
Bilayer conguration and mechanical properties of the chitosan scaffold
On the contrary to the approximately 100 mm thick and relatively dense structure of BAMG with a rough side and a smooth side, the chitosan scaffold presented a tightly interfaced bilayer conguration of approximately 600 mm thickness ( Fig. 2A, ESI  Fig. 1 †) . The asymmetric bilayer chitosan scaffold consisted of a membrane-like compact layer serving as the water barrier towards the bladder cavity, and a sponge-like porous layer for regenerated tissues ingrowth towards the peritoneal cavity (ESI Fig. 2 †) . The porous layer of chitosan had pores on its surfaces and internal space, ensuring plenty of space for the ingrowth of regenerative cells. The pore size is 0.1205 AE 0.005900 mm, the porosity is 93.02 AE 0.4470%, the pore interconnectivity is (1876 AE 257.6)/mm 3 . Meanwhile, the compact membrane possessed a dense texture with no apparent pore even at high magnication. Although the high porosity reduced the mechanical strength of the porous layer, the compact layer endowed the entire bilayer chitosan scaffold with stronger mechanical properties than BAMG. Despite its similar maximum load with BANG (9.79 AE 3.01 vs. 5.65 AE 2.73 N, P ¼ 0.15) (Fig. 2B) , the chitosan scaffold performed signicantly better in elastic modulus than BAMG (18.61 AE 0.48 vs. 12.95 AE 2.34 MPa, P ¼ 0.01) (Fig. 2C) . These results indicated that the chitosan scaffold had higher porosity and better mechanical properties than BAMG.
Characteristics of the animal models
All animals survived for the experimental period. Both scaffolds groups gained similar body weight with the control group. No bladder calculus was observed in the cystotomy group. The chitosan and BAMG groups had comparable bladder calculi (Table 2) , whose majority composition was ammonium magnesium phosphate. These results suggested that the chitosan scaffold did not affect the metabolism of the animals drastically.
The safety of scaffolds is of prior concern for clinical application, as well as the biodegradability in the regeneration process. Unlike the acidic remnants produced by degrading synthetic polymers of PGA/PLGA, the bilayer chitosan scaffold is metabolized into non-toxic D-glucosamines by lysozymes and tuned with suitable degradation speed for bladder repair, which alleviates the systematic toxicity and the local inammation reaction, and eliminates the risk of nidus for large bladder calculus. 28 Although a small quantity of bladder calculus was induced by the chitosan scaffold, it facilitated bladder regeneration with trivial scaffold shrinkage, brosis and metabolic disturbance.
Morphological restoration in gross appearance and retrograde cystography
At 21 days, both scaffolds entirely supported the original implantation areas with trivial brosis and contracture, which presented as small depressions in the bladder wall on retrograde cystography (Fig. 3 ). They were nally replaced by de novo host bladder tissue with remaining marking sutures at 70 days. The regenerated bladder walls in the chitosan group recovered to smooth oval shape, but the original defect site in the BAMG group still presented an irregular shape with depression under cystography. There was no leakage of contrast medium, stula, or diverticulum in all rats. These results suggested that the chitosan scaffold could lead to better morphological regeneration of the bladder wall aer bladder augmentation.
Improved bladder smooth muscle regeneration and vessel numbers by the chitosan scaffold
When focusing on the regenerated area, both scaffolds were lined with multilayer urothelium bordered by lamina propria at 21 and 70 days. Sparse smooth muscle bundles concentrated at the borders of the regeneration areas at 21 days, and traversed the entire width of the implants at 70 days aer surgery (Fig. 4) . In addition, histological comparison among groups were analyzed by immunouorescence (Fig. 5A ). There were more CK-positive areas in the chitosan and BAMG groups compared with the cystotomy group at 70 days (P < 0.01) (Fig. 5B) . The urothelial layer in the chitosan and BAMG groups presented irregular hyperplasia (Fig. 5A) . The chitosan group showed more a-SMA-positive smooth muscle cells than the BAMG (P < 0.01), which was close to that of cystotomy groups (P > 0.05) (Fig. 5C ). The same tendency was also observed with respect to CD31-positive vessel numbers. The mean number of CD31-positive vessels was similar in the chitosan and cystotomy groups (P > 0.05), which were signicantly higher than that of the BAMG group (P < 0.01) (Fig. 5E) . However, CD31-positive vessel diameter was comparable in the chitosan and BAMG groups, but was signicantly lower in the chitosan group compared with the cystotomy group (P < 0.01) (Fig. 5F ). Both chitosan and BAMG groups presented lower rates of NeuNpositive cells than that of the cystotomy group (P < 0.01) (Fig. 5D ). These histology results suggested that the chitosan scaffold could lead to proper bladder wall regeneration, expect for vessel diameters and innervation.
Simple application of BAMG had been reported to facilitate multi-layer urothelium regeneration in 60-70% partial cystectomy, 17 which demonstrated the high regenerated potency of urothelium. There was abundant regenerated urothelium in both chitosan and BAMG groups at 21 days, and developed to multi-layer structure with hyperplasia at 70 days. The urothelial hyperplasia was also found in regenerated bladder tissue supported by BAMG-silk broin at 12 weeks in our previous study, which was associated with chronic local inammation of macrophages. 23 This conclusion was veried by the majority composition of bladder calculus, ammonium magnesium phosphate, which was recognized to be caused by the inam-matory response.
29 Anti-inammation approaches were desirable under comprehensive examination.
The insufficient smooth muscle regeneration, angiogenesis and resultant impeded function were major problems of the biological scaffolds lack adequate porosity. In its rst published clinical trial for bladder augmentation, SIS repaired 5 patients suffering from bladder extrophy with disappointing histological results of smooth muscle, which was conrmed by the functional tests with a low increase of bladder capacity and compliance at 6 and 18 months respectively. 12 Although the bladder capacity and compliance were greatly improved by SIS in patients with myelomeningocele or spinal cord injury in a recent study, smooth muscle was unfavorably regenerated in small amounts. 30 The favorable regeneration of a-SMA-positive smooth muscle bundles in the chitosan group was partially credited to its increased porosity. In addition, the good biocompatibility of chitosan with smooth muscle cells should be noted for this phenomenon. 31 Three mechanisms may explain smooth muscle regeneration in the chitosan scaffold: (a) mature cells migration in the neighborhood; (b) dedifferentiation of mature cells prior to migration and redifferentiation; and (c) myobroblasts inltration followed by differentiation into smooth muscle cells. 32 The clinical impotency to facilitate smooth muscle regeneration of SIS was consolidated by its counterpart BAMG in our previous study in animal models, which was associated with the paucity in angiogenesis.
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Improper nerve regeneration would impede bladder functional restoration on the long term. 33 Although chitosan was shown to promote neural cells attachment and differentiation, 34 the re-innervation rate still could not recover to normal levels by the bilayer chitosan scaffold aer 70 days. It was reported that chitosan bers supported the adhesion, migration, and proliferation of Schwann cells, which allowed for axonal regeneration in the peripheral nervous system. 35 In vivo studies also suggested that chitosan-based membranes showed promising results regarding its applications in peripheral nerve engineering. 36 One possible explanation of the impeded innervation in chitosan group is that the process of nerve regeneration could take as long as 20 weeks. 37 As a result, a longer repair time is required unless the nerve regeneration would be accelerated.
Augmented bladder capacity with physiological compliance aer bladder augmentation by chitosan scaffold All three groups exhibited regular lling and voiding phases with the normal micturition patterns without signs of hypercontraction, obstruction, or irritation (Fig. 6A) . Threshold pressures were comparable between the chitosan and cystotomy groups, while the BAMG group showed signicant gain in threshold pressure compared to the cystotomy group (P < 0.05). Basal and peak pressures were comparable among the three groups (Fig. 6B) . Voiding volume and bladder capacity were signicantly enlarged to nearly 1.5-fold aer bladder augmentation with the chitosan scaffold and BAMG compared to the cystotomy group (P < 0.01 for voiding volume, P < 0.001 for bladder capacity). There were no signicant differences in residual volume among the three groups (Fig. 6C) . The compliance of the chitosan group (0.12 AE 0.020 ml per cmH 2 O) recovered to normal levels as in the cystotomy group (0.13 AE 0.015 ml per cmH 2 O), and was signicantly higher than that of the BAMG group (0.060 AE 0.010 ml per cmH 2 O) (P < 0.01) (Fig. 6D) . These results suggested that the regenerated bladder using the chitosan scaffold led to appropriate bladder function.
Scaffold porosity has long been regarded to affect angiogenesis and the development of functional tissue in bladder reconstruction. [38] [39] [40] The bilayer chitosan scaffold fostered more angiogenesis than BAMG by achieving comparable vessel numbers with control group. It was consistent with a previous study that a porous silk broin/chitosan blend scaffold prompted uniform vascularization in hernia repair when compared to relative dense acellular dermal matrix. 41 Moreover, approximate 10% increase of porosity promoted smooth muscle regeneration and vessel density in smooth muscle cells-seeded composite scaffold of BAMG and electro-spun PLGA scaffold.
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In the present study, the bladder was augmented by the chitosan scaffold with 1.5-fold capacity with normal compliance. The promoted bladder function is partially attributed to the increased smooth muscle proportion, whose contractile ability was closely linked to bladder function. 42 In addition, the controllable porosity of chitosan scaffolds was benecial to angiogenesis, which is fundamental in supporting the survival and function of the regenerated so tissues.
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Chitosan scaffold enhanced angiogenesis through the SDF1a/CXCR4 pathway Next, we formed a preliminary exploration of the possible effects of the chitosan scaffold on angiogenesis. Therefore, we analyzed the expression of VEGF and VEGFR2. The results showed that the SDF-1a and CXCR4 mRNA was upregulated in the chitosan group compared to the BAMG group (P < 0.05 and P < 0.001, respectively) ( Fig. 7A and B, ESI Table 1 and ESI Fig. 3 †) , which were consistent with their protein expressions (Fig. 7E) . SDF-1a is an upstream protein of the VEGF, and has many functions, including synergetic angiogenetic effects with VEGF and chemotaxis of endothelial progenitor cells. 44, 45 We found that VEGF and VEGFR2 were signicantly increased in the chitosan group compared to the BAMG group (Fig. 7) , both at the transcriptional and protein levels, suggesting that the enhanced angiogenetic potential of the chitosan scaffold was associated with the activation of the SDF-1a/CXCR4 pathway.
The underlying mechanisms of larger porosity resulting in increased regeneration of smooth muscle and angiogenesis are still unclear. One possible explanation is that blood vessel inltration happens more rapidly as the density of the pores increases. 46 It was also reported that a mesoporous glass nanolayer increased the gene expression of VEGF and hypoxia inducible factor-1 in human umbilical vein endothelial cells.
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Diffusion-limitation is an ever-present problem in tissue engineering, and scaffolds of any reasonable magnitude that fail to account for diffusion will ultimately suffer from areas of hypoxia. On the basis of this study, it was speculated that the activation of the hypoxia-related SDF-1a/CXCR4 pathway by the bilayer chitosan scaffold could be another important factor contributing to its enhanced angiogenic effects. The hypoxia stimulation caused by the regeneration process in the porous chitosan scaffold activated the SDF-1a/CXCR4 pathway by secreting SDF-1a and expressing CXCR4, regulating the mobilization and chemotaxis of hemangioblasts, secretion of matrix metalloproteinases for enhancing endothelial progenitor cell engrament, secretion of angiopoietic factors such as VEGF, and reduced apoptosis of endothelial cells. 48 In the present study, the chitosan scaffold upregulated the gene and protein expression of VEGF and its receptor VEGFR2 in bladders, which then induced hemangioblasts to form angiogenic network structures. The synergistic effects of SDF-1a and VEGF stimulated the proliferation and tube formation of endothelial cells, which further enhanced angiogenesis. 49 Nevertheless, the development of blood vessels in tissue engineering is a complicated process involving numerous angiopoietic growth factors. 50 More efforts should be made to determine the detailed mechanisms of the angiogenic potential of the chitosan scaffold and enhance the maturity of the regenerated blood vessels. Fig. 7 The chitosan scaffold enhanced angiogenesis by inducing VEGF through the activation of the SDF-1a/CXCR4 pathway. Expression levels of SDF-1a (A), CXCR4 (B), VEGF (C), and VEGFR2 (D) were evaluated by qRT-PCR using the bladders of the chitosan, BAMG, and cystotomy groups at 70 days post-implantation. (E) Western blot analysis of SDF-1a, CXCR4, VEGF, and VEGFR2 in the bladder of the three groups at 70 days post-implantation. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the cystotomy group;
